Skip to main content
. 2020 Jun 8;16:1744806920931737. doi: 10.1177/1744806920931737

Figure 8.

Figure 8.

The BMSC administration blocked the effects produced by antagomir-547-5p application. (a) and (b) Summary data of normalized changes in miR547-5p, IL-33 or ST2 mRNAs in the DRG (a) and SDH (b) to that in naive rats (= 1, dashed line). (c) and (d) Examples of Western blots; Antagomir-547-5p/BMSCs: Antagomir-547-5p was i.t. infused into rats pretreated with BMSCs (1 × 106 cells in 0.3 ml PBS). (e) and (f) Summary data of normalized changes in IL-33 and ST2 proteins in the DRG (e) and SDH (f) to that in naive rats (= 1, dashed line). (g) Summary data (mean ± SD) showing effects of the i.t. administration of antagomir-547-5p (20 µM) on the MWT and TWL of rats pretreated with BMSCs (see Supplementary Figure 5(e)). The black arrowheads indicate the i.t. infusion of antagomir-547-5p. Values in brackets indicate the number of rats tested.

DRG: dorsal root ganglia; SDH: spinal dorsal horn; BMSC: bone marrow stromal cell; IL33: interleukin-33; ST2: suppressor of tumorigenicity 2; MWT: mechanical withdrawal threshold; TWL: thermal withdrawal latency.